Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Best Standard of Care Clear all
Active, not recruiting Not applicable Interventional

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

NCT03377491
View directory record Official record
Conditions
Pancreas Adenocarcinoma
Interventions
NovoTTF-200T, Gemcitabine, nab paclitaxel
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting No phase listed Observational

ViBandz Feasibility Study

NCT07458568
View directory record Official record
Conditions
Pediatrics, Neurologic Dysfunction, Vibration Therapy
Interventions
ViBandz
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Months to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

NCT02149108
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nintedanib (BIBF 1120), Placebo, BSC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Plainville, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Effect of Early Rest on Recovery From Pediatric Concussion

NCT01101724
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion, Post-concussive Syndrome
Interventions
Mandated Rest, Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
11 Years to 22 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)

NCT05664867
View directory record Official record
Conditions
Hereditary Cancer Syndrome
Interventions
Mainstream Genetic Testing Model, Enhanced Standard of Care Model
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial

NCT06445192
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Best Practice, Biospecimen Collection, Exercise Counseling, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Questionnaire Administration, Telemedicine
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional

SLIP II Registry: Spinal Laminectomy Versus Instrumented Pedicle Screw Fusion

NCT03570801
View directory record Official record
Conditions
Lumbar Spondylolisthesis, Grade 1 Spondylolisthesis, Lumbar Spinal Stenosis, Degenerative Spondylolisthesis
Interventions
Expert Panel Review
Other
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

NCT00379470
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

NCT03596086
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade III
Interventions
ADV/HSV-tk (gene therapy)
Drug
Lead sponsor
David Baskin MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer

NCT03102866
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Best Practice, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions
Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration
Other · Procedure · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
153
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

NCT05893420
View directory record Official record
Conditions
Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Interventions
eCARTv5 clinical deterioration monitoring, Standard of care control
Device · Other
Lead sponsor
AgileMD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Active, not recruiting Phase 2 Interventional

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

NCT03844620
View directory record Official record
Conditions
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Best Practice, Laboratory Procedure, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Enrolling by invitation Phase 4 Interventional

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

NCT07230340
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Amnion-Intermediate-Chorion, Standard of Care (SOC)
Other · Procedure
Lead sponsor
Cellution Biologics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

NCT06568016
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Communication Intervention, Coordination, Educational Intervention, Electronic Health Record Review, Informational Intervention, Interview, Patient Navigation, Referral, Text Message-Based Navigation Intervention
Other · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Phase 3 Interventional Results available

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

NCT03422198
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma, Uterine Corpus Sarcoma
Interventions
Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
5
States / cities
Palo Alto, California • Maywood, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Completed No phase listed Observational

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

NCT05458258
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Myeloid
Interventions
Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test
Device · Other · Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
60 Years and older
Enrollment
239 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT00916409
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
NovoTTF-100A device, Temozolomide
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study

NCT04783168
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Best Practice, Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers

NCT06709404
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Telemedicine, Survey administration, Electronic health record review, Best Practice
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 11:15 PM EDT